It is probably time to be bullish as an investor. But remember two things. One: Valuations are still not cheap. Two: Because it is over and...

When prices fall, caution comes naturally. Investors hesitate, portfolios are reviewed less often, and even optimists become careful. But w...

A gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...

As the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...

As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...

India's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...

There are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...

India's government is taking emergency steps to ensure cancer patients get vital drugs. Cisplatin and carboplatin, crucial chemotherapy age...

India continues its strong support for Afghanistan, reaffirms MEA. The nation is focused on peace, stability, and development. This include...

At a time when there are so many headwinds for the markets, it is tough to imagine that things can get better. But sentiment is a fickle th...

A doctor shared the story of a BMW-driving professional earning ₹40 lakh annually who feels poor, highlighting how shifting lifestyles and ...

Major private equity firms are vying for a stake in Cloudnine, a leading maternity and paediatric care chain. This intense competition high...

As global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...

A 61-year-old woman endured eight months of severe pain, initially treated for acidity. Doctors eventually found a rare paraesophageal hiat...

The study, which followed patients for over five years, found that those ⁠who received ⁠the regimen were nine times more likely to have lit...

Novartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, e...

Sir H.N. Reliance Foundation Hospital has been ranked the country's leading multi-specialty institution in the Times of India Critical Care...